Alkeon Capital Management
KPTI icon

Alkeon Capital Management’s Karyopharm Therapeutics KPTI Stock Holding History

Alkeon Capital Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-130,773
Closed -$12.6M – 151
2021
Q4 		$12.6M Hold
130,773
– – 0.02% 134
2021
Q3 		$11.4M Sell
130,773
-46,772
-26% -$4.86M 0.02% 150
2021
Q2 		$27.5M Sell
177,545
-335
-0.2% -$48.6K 0.04% 131
2021
Q1 		$28.1M Buy
177,880
+119
+0.1% +$25.1K 0.04% 128
2020
Q4 		$41.3M Buy
177,761
+33,434
+23% +$7.75M 0.07% 120
2020
Q3 		$31.6M Buy
144,327
+6,667
+5% +$1.63M 0.06% 112
2020
Q2 		$39.1M Sell
137,660
-6,667
-5% -$1.97M 0.1% 104
2020
Q1 		$41.6M Buy
144,327
+135,994
+1,632% +$37.5M 0.18% 89
2019
Q4 		$2.4M Buy
+8,333
New +$1.81M 0.01% 124

Other funds holding KPTI

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ITP
Iron Triangle Partners Cos Cob, Connecticut $875M AUM 49.85% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Alkeon Capital Management's KPTI Position: Q1 2022 in Review

Alkeon Capital Management sold out of Karyopharm Therapeutics (KPTI) in Q1 2022, closing a stake of 130,773 shares — an estimated $12.6M sold.

Alkeon Capital Management first reported a position in KPTI in Q4 2019 and held it in 9 quarters. The position peaked at $41.6M in Q1 2020. 139 funds tracked by Wall St. Rank hold KPTI as of Q1 2022.

  • Alkeon Capital Management reported no remaining Karyopharm Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Alkeon Capital Management sold 130,773 Karyopharm Therapeutics shares in Q1 2022, an estimated $12.6M.
  • Alkeon Capital Management first reported a position in Karyopharm Therapeutics in Q4 2019 and held it in 9 quarters.
  • Alkeon Capital Management's Karyopharm Therapeutics position peaked at $41.6M in Q1 2020.
  • 139 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q1 2022.

Based on Alkeon Capital Management's 13F filing for Q1 2022, filed 16 May 2022.